The FDA has expanded the indication of 3M’s Tegaderm CHG Chlorhexidine Gluconate I.V. securement dressing to include catheter-related bloodstream infections (CRBSI).
The expanded indication is supported by a clinical trial that found the securement dressing reduced CRBSI by 60 percent in patients with central and arterial lines.
The dressing is a translucent, gel pad applied to the area where an I.V. is placed to allow healthcare professionals to monitor the insertion site for early identification of complications and to minimize catheter movement and dislodgement. — Cynthia Jessup